Treatments
SENTINEL LYMPH NODE
Patients were treated with neoadjuvant camrelizumab plus chemotherapy every three-week for six cycles. Camrelizumab was administered intravenously at 200 mg on day one of every three-week cycle. Chemotherapy consisted of nab-paclitaxel at 125 mg/mPatients who either discontinued or completed the neoadjuvant therapy could undergo surgery as clinically indicated. Definitive surgery (breast-conserving surgery or mastectomy with sentinel lymph node biopsy or axillary lymph node dissection) was performed according to the guideline and institutional standard procedures. Postoperative adjuvant therapy was at the discretion of the treating physicians.